Navigation Links
Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
Date:9/5/2007

ANN ARBOR, Mich., Sept. 6 /PRNewswire/ -- Terumo Heart Inc. announced today that it is planning a European Launch Symposium at the European Association of Cardio-Thoracic Surgeons (EACTS) meeting in Geneva, Switzerland on September 17, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061027/DEF004LOGO

http://www.newscom.com/cgi-bin/prnh/20070227/CLTU043LOGO )

A summary of the European Clinical Trial results for the company's DuraHeart(TM) Left Ventricular Assist System (LVAS) will be presented by Dr. Aly El-Banayosy from the Heart Center Nordrhine-Westaflen, Bad Oeynhausen, Germany. This will be followed by a presentation from Dr. Eric Rose, Professor of Surgery at Columbia University Medical Center in New York, entitled "The Emerging New Era of Mechanical Circulatory Support".

The EACTS meeting will mark the official launch of the DuraHeart LVAS. The device has been on the market in Europe for several months and is experiencing significant interest since achieving a CE Mark earlier in the year.

The DuraHeart LVAS is a 3rd generation circulatory support device with full magnetic levitation, intended to provide cardiac support for patients who are at risk of death due to end-stage left ventricular failure. It is the only approved implantable Left Ventricular Assist System combining a centrifugal pump with magnetic levitation of the impeller, providing exceptional reliability and minimizing the potential for blood damage and thrombus. The DuraHeart System is not available in the United States.

Terumo Heart Inc. is a U.S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the innovation and introduction of products to improve the quality of healthcare for the heart failure pat
'/>"/>

SOURCE Terumo Heart Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
4. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
5. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
6. Drug for Treatment of Heart Failure Does Not Improve Survival, Compared to More Widely-used Medication
7. deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack
8. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
9. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
10. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2008)...RNewswire-FirstCall/ -- BioMarin,Pharmaceutical In... first,patient has initiated treatment in the Phas...nt phenylalanine ammonia lyase) for the treatment ... conclude enrollment in the,fourth quarter of 2008... and hope to address the,entire spectrum of PKU pa...
(Date:5/20/2008)...lysis of US Employer Claims Suggests a Benefit,of ...m Among Employees with Infla...ire/ -- Data from a new analysis of the,Active Ulc...at at week 8,more than 60 percent of patients wit... (UC) receiving REMICADE(R) (infliximab) achieved,...
(Date:5/20/2008)...ith HALO device leads to 100% patient response ...lif., May 20 /- BARRX Medical, Inc., ...sophagus, today announced the,publication of two r...tion,rate for early esophageal cancer and pre-canc...d by ablation therapy with the HALO ablation,syste...
(Date:5/20/2008)...RNewswire-FirstCall/ -- Palatin Technologies,Inc....n initiated in a Phase,2a clinical study of PL-399...or A agonist, in subjects with controlled hyperten...-blinded, and will include up,to five cohorts rece...l be,included, with six active subjects and one pl...
Breaking Medicine Technology:BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU 2BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU 3New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 2New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 3New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 4New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 5New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 6New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 8Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination 2Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination 3Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994 2Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994 3Dr Fay Raines From the University of Alabama in Huntsville Assumes Presidency of the American Association of Colleges of Nursing 16736 1Dr Fay Raines From the University of Alabama in Huntsville Assumes Presidency of the American Association of Colleges of Nursing 16736 2Dr Fay Raines From the University of Alabama in Huntsville Assumes Presidency of the American Association of Colleges of Nursing 16736 3Dr Fay Raines From the University of Alabama in Huntsville Assumes Presidency of the American Association of Colleges of Nursing 16736 4U S Pharmacopeia Aiding FDA in Improved Tests for Heparin Contamination 16733 1U S Pharmacopeia Aiding FDA in Improved Tests for Heparin Contamination 16733 2CVS Caremark Charity Classic Golf Tournament Unveils 10th Anniversary Field 16730 1CVS Caremark Charity Classic Golf Tournament Unveils 10th Anniversary Field 16730 2CVS Caremark Charity Classic Golf Tournament Unveils 10th Anniversary Field 16730 3Northwest Hospital 26 Medical Center Hosts Health 26 Wellness Pavilion At Second Annual King 5 Healthy Living Expo 16727 1Northwest Hospital 26 Medical Center Hosts Health 26 Wellness Pavilion At Second Annual King 5 Healthy Living Expo 16727 2
...April 12, 2007,/PRNewswire-FirstCall/ -- Data anal...l trial program ever undertaken in the renal,anemi... the,investigational anemia therapy MIRCERA(TM) fo...ronic kidney disease (CKD) in,patients on dialysis...sented at the National Kidney Foundation 2007 Spri...
... /PRNewswire/ -- Mersana, a,cancer therapeutics co... studies with its lead product candidate, XMT-1001...ual Meeting of the,American Association of Cancer ...Angeles, CA. Full text of the abstracts can be,vie...k" href=,"http://www.aacr.org/">http://www.AACR.or...
Other Medicine Technology:Data Analyses Outline Efficacy and Safety of Mircera for the,Treatment of Renal Anemia Associated With Chronic Kidney Disease 2Data Analyses Outline Efficacy and Safety of Mircera for the,Treatment of Renal Anemia Associated With Chronic Kidney Disease 3Data Analyses Outline Efficacy and Safety of Mircera for the,Treatment of Renal Anemia Associated With Chronic Kidney Disease 4Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001,at American Association of Cancer Research Annual Meeting 2
(Date:5/20/2008)...nical settings, DNA microarrays are currently unsu...on formalin-fixed paraffin-embedded tissues is req...markers for identifying the prognosis of gastric c...eam led by Professor Zhong-Sheng Zhao, is describe..., 2008 in the World Journal of Gastroenterology. ,...
(Date:5/20/2008)...nd-stage liver disease would benefit from liver su...tion of hepatic functions or to enable bridging to...patients, general condition, including cardiovascu...patic encephalopathy. Studies evaluating the hemod...is during extra-corporal intervention remain scarc...
(Date:5/20/2008)...H+ exchanger (NHE1) is a transmembrane protein fou...s to evacuate excessive H+ in the cytoplasm by mea...llular pH value. Inhibition of the upregulation of...cells can induce intracellular acidification, resu...l for the treatment of tumors. , This study, per...
(Date:5/20/2008)...., May 20 /PRNewswire-FirstCall/ -- Perrigo Compan...ph C. Papa, Perrigo,s,Chairman and CEO will presen...re Conference on Wednesday, May 21, at 10:00 a.m. ... be webcast on the following link, http://www.vera...cfm ., Perrigo Company is a leading global healt...
Breaking Medicine News(10 mins):
... are insufficient doctors specializing in sports m...012 Olympics// that is to be hosted by UK. Present...o recruit one specialist each, for the treatment o... as to help tackle the rising problem of obesity. ...
...revention of chikungunya and dengue fever in the s...blic Health//. Aedes aegypti, mosquito is the com...dengue causing virus. Hence, the state has taken u...me involving 35,000 health workers and volunteers....
...urvey has revealed that extreme and prolonged stre... by an inability to switch off, could lead to grav...e survey also found that not being able to sleep i... rigors of coping with every day life. They are no...
...ons commonly sold on the street, causes the abnorm... a process causing heart enlargement that can ulti...at the University of South Florida College of Medi...ital. The study was published in the July 2006 is...
Other Medicine News:Health News:Sports Doctors too few for 2012 Olympics 2Health News:Researchers Identify Key Step in Cocaine-Induced Heart Enlargement, Sudden Death 2
The OX-2 is configured asstandalone or handheld unit, designed for hospital, transport and home use.
The 8600 Series Tabletop/Portable Digital Pulse Oximeter provides a simple universal tool for patient monitering. From transport applications to continuous monitoring, the 8600 has earned the confide
Halogen-free immersion oil based on ester oil.
Immersion oil composed on polyester polyol, diphenyl cresyl phosphate and tricyclodecane dimethanol.
Medicine Products: